NEW YORK (Reuters Health) — HER2-low-positive breast cancer, readily identified by standardized central pathology, is a distinct subtype with a specific biology and different response to therapy and prognosis, report researchers in Germany. “It is reassuring that the subgroup of HER2-low-positive tumors can be detected in central pathology datasets that were generated based on the […]

The PD-L1 inhibitor atezolizumab (Tecentriq) combined with carboplatin has shown signs of clinical activity in women with metastatic invasive lobular breast cancer (ILC) according to the first results to come from the ongoing GELATO trial. The 6-month objective response rate was 19%, based on 4 of 21 patients who could be evaluated exhibiting a partial […]